DK0792292T4 - Orphan-receptor - Google Patents

Orphan-receptor

Info

Publication number
DK0792292T4
DK0792292T4 DK96931047T DK96931047T DK0792292T4 DK 0792292 T4 DK0792292 T4 DK 0792292T4 DK 96931047 T DK96931047 T DK 96931047T DK 96931047 T DK96931047 T DK 96931047T DK 0792292 T4 DK0792292 T4 DK 0792292T4
Authority
DK
Denmark
Prior art keywords
amino acid
acid sequence
receptor
relates
disorders
Prior art date
Application number
DK96931047T
Other languages
English (en)
Other versions
DK0792292T3 (da
Inventor
George G J M Kuiper
Eva Enmark
Jan-Ake Gustafsson
Original Assignee
Karobio Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451339&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0792292(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9518272.1A external-priority patent/GB9518272D0/en
Priority claimed from GBGB9605550.4A external-priority patent/GB9605550D0/en
Priority claimed from GBGB9607532.0A external-priority patent/GB9607532D0/en
Priority claimed from GBGB9609576.5A external-priority patent/GB9609576D0/en
Application filed by Karobio Ab filed Critical Karobio Ab
Application granted granted Critical
Publication of DK0792292T3 publication Critical patent/DK0792292T3/da
Publication of DK0792292T4 publication Critical patent/DK0792292T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK96931047T 1995-09-08 1996-09-09 Orphan-receptor DK0792292T4 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9518272.1A GB9518272D0 (en) 1995-09-08 1995-09-08 Orphan receptor
GBGB9605550.4A GB9605550D0 (en) 1996-03-15 1996-03-15 Orphan receptor
GBGB9607532.0A GB9607532D0 (en) 1996-04-11 1996-04-11 Orphan receptor
GBGB9609576.5A GB9609576D0 (en) 1996-05-08 1996-05-08 Orphan receptor
PCT/EP1996/003933 WO1997009348A2 (en) 1995-09-08 1996-09-09 Orphan receptor

Publications (2)

Publication Number Publication Date
DK0792292T3 DK0792292T3 (da) 2000-02-07
DK0792292T4 true DK0792292T4 (da) 2009-07-20

Family

ID=27451339

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96931047T DK0792292T4 (da) 1995-09-08 1996-09-09 Orphan-receptor

Country Status (12)

Country Link
US (2) US5958710A (da)
EP (2) EP0935000A3 (da)
JP (4) JP3131649B2 (da)
KR (1) KR100263137B1 (da)
AT (1) ATE183516T1 (da)
AU (1) AU715528B2 (da)
CA (1) CA2201098C (da)
DE (2) DE792292T1 (da)
DK (1) DK0792292T4 (da)
ES (1) ES2135249T5 (da)
GR (2) GR980300029T1 (da)
WO (1) WO1997009348A2 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2200423C (en) * 1996-03-26 2006-12-19 Sietse Mosselman Novel estrogen receptor
EP0866127A3 (en) * 1997-03-17 1999-12-22 Smithkline Beecham Plc HE8AN36, a steroid hormone receptor homolog
JP2002506433A (ja) * 1997-06-10 2002-02-26 カロ バイオ アクチェブラーグ エストロゲン・レセプター・リガンド
US7157568B1 (en) * 1997-08-05 2007-01-02 American Home Products Corporation Human estrogen receptor-β
US6222015B1 (en) 1997-09-08 2001-04-24 Merck & Co., Inc. Estrogen receptor
AU747049B2 (en) * 1997-09-08 2002-05-09 Merck Sharp & Dohme Corp. Estrogen receptor
GB9814620D0 (en) * 1998-07-06 1998-09-02 Karobio Ab Vasculoprotector
DE19839115A1 (de) * 1998-08-27 2000-03-09 Ihf Inst Fuer Hormon Und Fortp Klonierung und Expression von Rinder Estrogenrezeptor-beta
EP1400810A3 (en) * 1999-04-09 2005-03-02 Karo Bio Ab Estrogen receptors and bone disease
DK1165184T3 (da) * 1999-04-09 2004-04-13 Karobio Ab Estrogenreceptor-beta antagonisme og knoglesygdomme
AU2002247702A1 (en) * 2001-02-09 2002-08-28 Lion Bioscience Ag Novel cofactors of the estrogen receptor beta and methods of use
WO2002070697A1 (en) * 2001-03-02 2002-09-12 Lion Bioscience Ag Mammalian nuclear receptor l67 and methods of use
JP2005504032A (ja) 2001-07-31 2005-02-10 ファイザー・プロダクツ・インク エストロゲン・アゴニスト／アンタゴニスト、エストロゲン及びプロゲスチンの組み合わせを含む医薬組成物、キット及び方法
WO2003044006A1 (en) 2001-11-19 2003-05-30 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
AU2002353076A1 (en) * 2001-12-07 2003-06-23 Isis Pharmaceuticals, Inc. Antisense modulation of estrogen receptor beta expression
CA2365811A1 (en) * 2001-12-21 2003-06-21 Institut De Cardiologie A new gene therapy using antisense strategy to estrogen receptors (er .alpha. and/or er .beta.) to optimize vascular healing and cardioprotection after vascular injury
EP2298315A1 (en) 2002-08-28 2011-03-23 Harbor BioSciences, Inc. Therapeutic treatment methods
WO2004076504A2 (en) 2003-02-21 2004-09-10 Dow Global Technologies, Inc. Process for homo- or copolymerization of conjugated olefines
ATE406373T1 (de) 2003-04-21 2008-09-15 Lilly Co Eli Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
DE602004025460D1 (de) 2003-04-21 2010-03-25 Lilly Co Eli Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
EP1667955A2 (en) 2003-07-28 2006-06-14 SmithKline Beecham Corporation Cycloalkylidene compounds as modulators of the estrogen receptor
EP1709443A2 (en) * 2003-12-18 2006-10-11 Procognia, Ltd. Method for analyzing a glycomolecule
CN101052641A (zh) 2004-09-07 2007-10-10 惠氏公司 6H－[1]苯并吡喃并[4,3－b]喹啉及其作为雌激素药物的用途
GB0704407D0 (en) 2007-03-07 2007-04-18 Glaxo Group Ltd Compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4981784A (en) * 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5217867A (en) * 1988-11-30 1993-06-08 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
US5262300A (en) * 1988-11-30 1993-11-16 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
US5602009A (en) * 1988-12-23 1997-02-11 The Salk Institute For Biological Studies Dominant negative chimeras of the steroid/thyroid superfamily of receptors
ATE166360T1 (de) * 1989-03-17 1998-06-15 Salk Inst For Biological Studi Zusammensetzung und testverfahren eines elementes als antwort auf ein hormon
US5438126A (en) * 1989-09-11 1995-08-01 Arch Development Corporation Human thyroid hormone receptor DNA
AU1173995A (en) * 1993-11-10 1995-05-29 Arch Development Corporation Ubiquitous nuclear receptor: compositions and methods
CA2200423C (en) * 1996-03-26 2006-12-19 Sietse Mosselman Novel estrogen receptor

Also Published As

Publication number Publication date
AU715528B2 (en) 2000-02-03
JP2005204667A (ja) 2005-08-04
JP2002010788A (ja) 2002-01-15
DE69603827T3 (de) 2009-11-05
CA2201098C (en) 2001-03-27
AU6988096A (en) 1997-03-27
EP0792292B2 (en) 2009-04-15
EP0792292A2 (en) 1997-09-03
GR3031618T3 (en) 2000-01-31
CA2201098A1 (en) 1997-03-13
EP0935000A3 (en) 1999-09-08
EP0935000A2 (en) 1999-08-11
WO1997009348A3 (en) 1997-04-24
KR100263137B1 (ko) 2000-08-01
EP0792292B1 (en) 1999-08-18
WO1997009348A2 (en) 1997-03-13
DE69603827D1 (de) 1999-09-23
DE792292T1 (de) 1998-09-03
JPH11502417A (ja) 1999-03-02
DK0792292T3 (da) 2000-02-07
ES2135249T3 (es) 1999-10-16
JP2005204666A (ja) 2005-08-04
US5958710A (en) 1999-09-28
US7132261B2 (en) 2006-11-07
US20030113803A1 (en) 2003-06-19
GR980300029T1 (en) 1998-04-30
ES2135249T5 (es) 2009-09-10
ATE183516T1 (de) 1999-09-15
JP3131649B2 (ja) 2001-02-05
DE69603827T2 (de) 2000-02-24

Similar Documents

Publication Publication Date Title
DE69603827D1 (de) Waisen-rezeptor
EP1028758A4 (en) METHOD FOR TREATING PROSTATE TUMORS WITH RADIOACTIVE COMPOSITIONS
BR9915679A (pt) Composições e métodos para aumentar a mineralização óssea
MX9700553A (es) Anticuerpos que activan un receptor de eritropoyetina.
BR9712589A (pt) Conjugado, composição farmacéutica, processos para tratar cáncer de próstata, para tratar hiperplasia prostática benigna, e, para fazer uma composição farmacêutica.
MXPA00012586A (es) Glicosulfopeptidos y metodos de sintesis y uso de los mismos.
AU6045398A (en) Androgen synthesis inhibitors
NO961706D0 (no) Sammensetning som særlig binder seg til kolorektale kreftceller, samt fremgangsmåte for anvendelse av samme
TR200000927T2 (tr) Prostaglandin agonistleri ve kemik bozukluklarının tedavisi
PL328858A1 (en) Immunogenous peptides
DE60045751D1 (de) Therapeutische Behandlung androgenrezeptorbedingter Leiden
DE69809726D1 (de) Substituierte analoge von indol-3-carbinol und von diindolmethan als antiestrogene
MX9708401A (es) Genes reguladores de la cromatina.
AP9801269A0 (en) Prostaglandin agonists.
UA66861C2 (uk) 2-феніл-1-[4-(2-аміноетокси)бензил]індол в комбінації з естрогенами, способи лікування та продукт для лікування
EP1089731A4 (en) COMPOSITIONS AND METHOD FOR TREATING INCREASED BLOOD CHOLESTEROL LEVELS
Banerjee et al. Distinct colchicine binding kinetics of bovine brain tubulin lacking the type III isotype of beta-tubulin
DE69720996D1 (de) Neue pharmazeutische zusammensetzungen von steroid-nitratester zur verwendung als enzündungshemmer
ATE279208T1 (de) Verfahren und stoffe zur behandlung des prostatakarzinomes
EP1089732A4 (en) COMPOSITIONS AND METHODS FOR TREATING INCREASED BLOOD CHOLESTEROL LEVELS
IL128872A0 (en) TNF-beta-like protein for treating prostate cancer and related nucleic acid molecules pharmaceutical compositions and methods
EE200000333A (et) Eesnäärmevähi ravis kasutatav konjugaat ning farmatseutiline kompositsioon ja selle valmistamismeetod
BR9808784A (pt) Método para o tratamento de doença mental em mamìferos e uma composição para o mesmo
NO972313D0 (no) Peptider som er i stand til å binde til GAP-protein-SH3-området, nukleotid-sekvenser som koder for dette samt fremstilling og bruk derav
Miller et al. Elevated intrinsic reactivity of seryl hydroxyl groups within the linear peptide triads His-Xaa-Ser or Ser-Xaa-His